RPL30 is a component of the large ribosomal subunit and serves as a structural constituent of the ribosome, which is a large ribonucleoprotein complex responsible for protein synthesis in the cell 12. Beyond its canonical ribosomal function, RPL30 has been identified as an antimicrobial protein capable of binding and killing both Gram-negative and Gram-positive bacteria through interaction with bacterial cell wall components including LPS, LTA, and PGN 3. The antimicrobial activity resides in the core region spanning residues 2-46 and operates via membranolytic action, including membrane depolarization, while showing no hemolytic activity against human red blood cells 3. Clinically, RPL30 has emerging significance as a biomarker. Overexpression of RPL30 is associated with adverse outcomes in medulloblastoma, particularly when located on chromosome 8 4. Additionally, anti-RPL30 antibodies show promise as diagnostic biomarkers for primary biliary cholangitis, especially in autoantibody-negative cases, achieving 100% specificity and 75% sensitivity 5. RPL30 expression has also been linked to tumor stemness and immune evasion in colorectal cancer progression 6, suggesting broader roles in cancer biology beyond its traditional ribosomal function.